Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10)

Inherited Epidermolysis Bullosa Clinical Trial

Official title:

Open, Prospective, Controlled Case Series Documentation to Compare Intra-individually the Efficacy and Tolerance of Sericare® Versus Non-adhesive Wound Dressing Alone in Accelerating the Epithelialization of Skin Lesions of Patients With Epidermolysis Bullosa Hereditaria

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01294241
• Other study ID #: BEB-10
• Status: Completed
• Phase: Phase 2
• First received: October 27, 2010
• Last updated: May 27, 2017
• Start date: November 2010
• Est. completion date: June 2011

Study information

• Verified date: May 2017
• Source: Amryt Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to compare intra-individually the reepithelialization of skin lesion(s) in inherited Epidermolysis bullosa (either 1 wound ≥10 cm2 and ≤200 cm2 in size divided in 2 equal halves or 2 comparable wounds of ≥5 cm2 each) treated with Oleogel-S10 and non-adhesive wound dressing versus non-adhesive wound dressing only.

Description:

This study was designed as an open-label, prospective, controlled, blindly evaluated, monocentric phase II case series documentation in patients with inherited Epidermolysis bullosa (EB). The investigator either identified 1 EB wound ≥10 cm2 and ≤200 cm2 in size and divided it into 2 halves or selected 2 comparable wounds of ≥5 cm2 each. One (half of the) EB wound was treated with Oleogel-S10 and non-adhesive wound dressing. The other wound (half) was covered with a non-adhesive wound dressing only (Mepilex®) as control. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'. This was an open-label study. The investigator, the participant, and the sponsor knew the identity of the treatment. Two independent experts were blind to treatment and assessed efficacy based on chronological series of cropped and coded photographs by wound (half) that were taken before start of treatment, during wound dressing changes and at the end of treatment on Day 14/Day 28.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: June 2011
• Est. primary completion date: June 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 95 Years

Eligibility

Inclusion Criteria:

1. Patients aged 1-95 years

2. Patient and/or his/her legal representative was informed, read and understood the patient information/informed consent form and gave written informed consent

3. Patients with inherited EB with at least 1 skin lesion between 10 cm2 and 200 cm2 (alternatively 2 comparable lesions of at least 5 cm2 each)

4. Patient and/or his/her legal representative was able and willing to follow study procedures and instructions including the following:

1. Application of Oleogel-S10 on (1 half of) the wound at every wound dressing change

2. Regular visits during the treatment period (14 days in 'recent wounds' to 28 days in 'chronic wounds')

5. Negative pregnancy test in women of childbearing potential within 7 days before start of treatment

6. Women of childbearing potential agreed to use an effective method of contraception (Pearl Index < 1, e.g. hormonal contraception including the combined oral contraceptive pill, the transdermal patch, and the contraceptive vaginal ring, intrauterine devices or sterilization) during treatment and for at least 6 months thereafter

7. Men of procreative capacity agreed to use an effective method of contraception during treatment and for at least 6 months thereafter

Exclusion Criteria:

1. Systemic treatment with steroids during the last 30 days

2. Uncontrolled diabetes mellitus or diabetic ulcers

3. Diseases or conditions that could, in the opinion of the investigator, interfere with the assessment of safety, tolerance or efficacy

4. Skin disorders adversely affecting wound healing or involving the areas eligible for study treatment

5. Hypersensitivity to the trial medication or surgical dressings to be used

6. Multiple allergic disorders

7. Administration of investigational drugs within 3 months before screening

8. Investigations or changes in management for an existing medical condition

9. Low probability to complete the study per protocol for whatever reason

Related Conditions & MeSH terms

• Epidermolysis Bullosa
• Inherited Epidermolysis Bullosa

Intervention

Drug:
• Oleogel-S10
1 cm or 125 µL or 115 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.

Device:
• Mepilex® soft silicone faced polyurethane foam dressing
Mepilex® soft silicone faced polyurethane foam dressing was changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.

Locations

Country	Name	City	State
Germany	EB Center at the Department of Dermatology, University Medical Center	Freiburg

Sponsors (1)

Lead Sponsor	Collaborator
Birken AG

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Intra-individual Difference in Reepithelialization of Wound (Halves) at Day 14 in 'Recent Wounds' or Day 28 in 'Chronic Wounds'	The primary end point was the progress of reepithelialization from baseline to either Day 14 ('recent wounds') or Day 28 ('chronic wounds') of the EB wound (half) treated with Oleogel-S10 and non-adhesive wound dressing (Mepilex®) intra-individually compared to the other wound (half) covered with non-adhesive wound dressing only (intra-individual comparison). Two independent experts were blind to treatment and assessed efficacy based on chronological series of cropped and coded photographs by wound (half) that were taken before start of treatment, during wound dressing changes and at the end of treatment on Day 14/Day 28. They evaluated each series and decided whether 1 wound (half) reepithelialized faster than the other ('winner'), or whether there was no difference in reepithelialization.	14 days for 'recent wounds', 28 days for 'chronic wounds'
Secondary	Percentage of Wound Epithelialization at Day 7±1	The secondary endpoint was the intra-individual difference in median percentage of wound epithelialization at Day 7±1. Sizes of wound areas were measured using a digital wound evaluation program from the EB Center at the Department of Dermatology, University Medical Center Freiburg.	Day 7±1
Secondary	Percentage of Wound Epithelialization at Day 14±1	The secondary endpoint was the intra-individual difference in median percentage of wound epithelialization at Day 14±1. Sizes of wound areas were measured using a digital wound evaluation program from the EB Center at the Department of Dermatology, University Medical Center Freiburg.	Day 14±1